Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
11/09/18
Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13th at 9:30 a.m. ET. A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres’ website. A replay will become available approximately one hour after the event and will be archived f... 
11/08/18
Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
- Kevin Horgan, M.D. an accomplished drug developer and immunology expert, hired as Chief Medical Officer - - Planning for two new microbiome clinical studies in ulcerative colitis and metastatic melanoma; Company expects to receive $40M in payments from Nestlé Health Science with SER-287 Phase 2b study start - - Conference call at 8:30 a.m. ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2018-- Seres Therapeutics,... 
11/05/18
Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 5, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on November 8, 2018 at 8:30 a.m. ET to discuss third quarter 2018 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 9877087. To j... 
EventsMore
Webcast ImageWebcast
Q3 2018 Seres Therapeutics, Inc. Earnings Conference Call (Replay)
11/08/18 at 8:30 a.m. ET
Q3 2018 Seres Therapeutics, Inc. Earnings Conference Call
Thursday, November 8, 2018 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Seres Therapeutics, Inc. at the Stifel 2018 Healthcare Conference (Replay)
11/13/18 at 9:30 a.m. ET
Seres Therapeutics, Inc. at the Stifel 2018 Healthcare Conference
Tuesday, November 13, 2018 9:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Download DocumentationCorporate Presentation

DateTitleRemind
Me
Prior to
Event
11/13/18 9:30 a.m. ET
Seres Therapeutics, Inc. at the Stifel 2018 Healthcare Conference
  
Stock Quote
NASDAQ:MCRB
$8.01
 + 0.01 (0.12%)
11/13/18 1:19 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.